Amylyx Pharmaceuticals

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. Founded in 2013 by Joshua Cohen, Justin Klee, and Kent Leslie, the company focuses on developing innovative therapies for neurodegenerative diseases and other challenging medical conditions. Their mission is to address significant unmet medical needs through rigorous scientific research and a deep understanding of the communities they serve. The company is advancing several investigational therapies, including Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism, AMX0035 for Wolfram syndrome and progressive supranuclear palsy, and AMX0114 for amyotrophic lateral sclerosis. Amylyx collaborates closely with the ALS community and various stakeholders in the medical field to enhance its research and development efforts. With a commitment to innovation and improving patient outcomes, Amylyx Pharmaceuticals is expanding its global presence, including a recent establishment of a subsidiary in Japan.

Pharmaceuticals Cambridge, United States ~166 employees NASDAQ: AMLX

Work at Amylyx Pharmaceuticals in HR or recruiting? Claim this page

Employees
166
+5.7% in the 3 months to Sep 2026
Revenue / employee
$527K
Revenue ~$87.4M
Stock
AMLX
NASDAQ
12-month attrition
11.1%
Tech: 12.5%
H1B sponsor
NA
Open jobs
30
Last 30 days

Headcount trend

Amylyx Pharmaceuticals went from 133 employees in Oct 2024 to 166 in Sep 2026. Apr to Sep 2026: 24 people joined, 4 left.

Org structure

Headcount by department

Other83
Operations36
Finance15
Marketing10
HR10
Engineering6
Sales4
Design1

Hiring now

1–8 of 26

Amylyx Pharmaceuticals FAQ

How many employees does Amylyx Pharmaceuticals have?

Amylyx Pharmaceuticals has about 166 employees, up 5.7% over the 3 months to Sep 2026.

What is Amylyx Pharmaceuticals's revenue per employee?

Amylyx Pharmaceuticals makes about $527K in revenue per employee, based on $87.4M annual revenue and 166 employees.

Is Amylyx Pharmaceuticals a public company?

Yes. Amylyx Pharmaceuticals is publicly traded under the ticker AMLX on NASDAQ.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.